

Human/Mouse/Rat Neuropilin-2 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF2215

DESCRIPTION		
Species Reactivity	Human/Mouse/Rat	
Specificity	Detects human, mouse, and rat Neuropilin-2 in Western blots.	
Source	Polyclonal Goat IgG	
Purification	Antigen Affinity-purified	
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Neuropilin-2 Gln23-Tyr855 Accession # Q7LBX6	
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.	
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS	

APPLICATIONS

DATA

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.				
	Recommended Concentration	Sample		
Western Blot	0.5 μg/mL	See Below		
Flow Cytometry	0.25 μg/10 ⁶ cells	HUVEC human umbilical vein endothelial cells		
Immunohistochemistry	5-15 μg/mL	See Below		
Simple Western	10 μg/mL	See Below		
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.			
Blockade of Receptor-ligand Interaction	ade of Receptor-ligand Interaction Human VEGF165 (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) to immobilized Recombinant Human Neuropilin-2 Fc Chimera (Catalog # 293-VE) t			

2215-N2) coated at 1 μg/mL (100 μL/well). At 20 μg/mL, this antibody will block >90% of the binding.



Neuropilin-2 by Western Blot. Western blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 0.5 Human/Mouse/Rat Neuropilin-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2215) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody Catalog # HAF109). A specific band was detected for Neuropilin-2 at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot

Immunohistochemistry



Neuropilin-2 in Human Pancreatic Cancer Tissue. Neuropilin-2 was detected in immersion fixed paraffinembedded sections of human pancreatic cancer tissue using Goat Anti-Human/Mouse/Rat Neuropilin-2 Antigen Affinitypurified Poly-clonal Antibody (Catalog # AF2215) at 5 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Rev. 6/3/2022 Page 1 of 2

biotechne

Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Human/Mouse/Rat Neuropilin-2 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF2215



- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution

BACKGROUND

Neuropilin-2 (Npn-2) is a 120 kDa, type I transmembrane (TM) glycoprotein that is related to the semaphorin receptor now known as Neuropilin-1 (1). Npn-2 is a complex molecule with multiple splice forms. Five transmembrane forms are known, and one 62 kDa soluble form has been identified (2). Based on the originally reported precursor size of 909 amino acids (aa), the "standard" precursor in human will have a 20 aa signal sequence, an 842 aa extracellular region, a 25 aa TM segment, and a 42 aa cytoplasmic tail (1). The extracellular region contains two N-terminal CUB (C1r/Ugef/BMP-1) domains, two jellyroll-shaped coagulation factor V type C domains, and a juxtamembrane MAM (meprin/A-5 protein/tyrosine phosphatase µ) domain (1, 3). The CUB and factor V domain are involved in VEGF and semaphorin binding. The MAM domain appears necessary for signaling through plexin-1 (4). The five transmembrane isoforms all share the same CUB, factor V and MAM domains. Splicing begins at as 809, seven amino acids after the end of the MAM domain, and it involves the end of the extracellular region, the TM segment. and the cytoplasmic domain (a total of 101 aa). Two of the four variants show a complete replacement of these 101 aa with a totally unrelated stretch of approximately 90 aa. This creates a new TM and cytoplasmic tail. These forms are called "Npn-2b" forms. Two other isoforms (plus the standard 909 aa form) retain the 101 aa stretch, and add either 17 or 22 aa to the end of the extracellular region. These forms are called "Npn-2a" forms. The isoform offered by R&D Systems is the "a" form with the 17 aa addition. This isoform shows 94% aa identity to the equivalent regions in mouse and rat Npn-2. The soluble form of Npn-2 is 555 aa in precursor length, and contains the two CUB domains plus the first 11/2 factor V type C domains (1). Npn-2 binds Sema3B through F, and VEGF isoforms 165, 145, PIGF-2, and VEGF-C (5). It is known to form homodimers and heterodimers with Npn-1, and it forms receptor complexes with plexin-1 and VEGF R1 (4, 5). Npn-2 is found on a variety of cell types including neurons (motor, autonomic, sensory), vascular endothelial cells, Schwann cells and pancreatic acinar cells.

References:

1. Chen, H. et al. (1997) Neuron 19:547.

٠

- 2. Rossignol, M. et al. (2000) Genomics 70:211.
- 3. He, Z. and M. Tessier-lavigne (1997) Cell 90:739.
- 4. Nakamura, F. and Y. Goshima (2002) Adv. Exp. Med. Biol. 515:55.
- 5. Neufeld, G. et al. (2002) Adv. Exp. Med. Biol. 515:81.

PRODUCT SPECIFIC NOTICES

This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for such purposes, contact The Regents of the University of California

U.S. Patent # 6,054,293, 6,623,738, and other U.S. and international patents pending

Rev. 6/3/2022 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449